TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
TriLink BioTechnologies (TriLink ® ), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility. The 32,000-square-foot facility was specifically designed for mRNA manufacturing to support late-phase drug developers from Phase 2 to commercialization via TriLink’s robust mRNA manufacturing capabilities. The milestone opening is expected to help advance the field of mRNA-based medicine as developers flock to leverage the promising modality for a growing list of indications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418722567/en/
TriLink BioTechnologies® Cuts Ribbon on New San Diego Facility for Late Phase mRNA Drug Substance Production (Photo: TriLink BioTechnologies®)
Located in the Sorrento Valley area of San Diego, the facility features individual Grade C cleanroom suites for mRNA manufacturing, increased mRNA capacity (1g to >100g per batch), comprehensive in-house analytical services, and laboratory space for on-site quality control testing. The manufacturing suites are outfitted with state-of-the-art equipment and ready to onboard clients with late-phase manufacturing needs.
“This facility is expected to help move the needle for life-saving breakthroughs in mRNA-therapeutics,” explained Kevin Lynch, Vice President & General Manager of TriLink’s GMP Operations. “The high-quality manufacture of mRNA drug substances is critical to ensuring the safety and efficacy of this new class of medicines for patients.”
Company and site leadership and industry guests gathered on April 17 to celebrate the facility’s grand opening with a ribbon cutting, expert-led panel discussion, and site tours – all centered around a core theme: Building the Future of mRNA. The thought-provoking panel included insights on the mRNA regulatory landscape, manufacturing evolution, and next-generation tools.
TriLink has reliably delivered GMP services to drug developers since the debut of its first cGMP facility in 2015. Since then, the company’s dedicated team of scientists has provided over 1,000 clients with custom mRNA synthesis, supported 350+ programs in biopharma development pipelines, and delivered over 100 GMP mRNA manufacturing batches.
“TriLink’s depth of industry experience – which spans over 25 years – coupled with its capabilities makes for an unmatched partner,” shared Drew Burch, President of Nucleic Acid Production. “This new facility codifies our commitment to advancing the field by playing a key role in the development of mRNA-based in vivo gene editing, gene-edited cell therapies, protein replacement therapies, cancer vaccines, and infectious disease vaccines.”
In addition to CDMO services and unique mRNA, oligonucleotide, NTP, and plasmid production capabilities, TriLink has developed the award-winning CleanCap® mRNA capping technology used in the majority of approved COVID-19 mRNA and saRNA vaccines, adding momentum to the rapidly growing field.
To learn more about TriLink’s products and services, visit trilinkbiotech.com.
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.
For more information, visit trilinkbiotech.com.
About Maravai LifeSciences
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit www.maravai.com.
Forward-looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements related to the expectation that the facility will help advance the field of mRNA-based medicine and will help move the needle for life-saving breakthroughs, constitute forward-looking statements identified by words like “expect,” “estimate,” “may,” “soon,” “nears,” “slated,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, operational risks and competition. These and other risks and uncertainties are described in greater detail in the “Risk Factors” section of our most recent Annual Report on Form 10-K, as well as other reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from those contemplated by these forward-looking statements, and therefore you should not rely upon them. These forward-looking statements reflect our current views and we do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240418722567/en/
Contact information
Investor Contact: Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com
Media Contact:
Liz Robinson of CG Life
TriLink BioTechnologies
+1 312-997-2436
lrobinson@cglife.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alipay Sees Tap! Users Pass 100 Million, Accelerating Payment and AI Innovations25.4.2025 05:30:00 EEST | Press release
Alipay Tap!, a QR code-based contactless payment and customer engagement solution introduced by Alipay in China in June 2024, reports today it has won over 100 million users within 11 months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424690776/en/ FamilyMart leverages Alipay Tap! to simplify payments and membership management. Alipay Tap! further simplifies the payment experience for both consumers and merchants compared to the “scan-and-pay” model ubiquitous in China. Users tap their unlocked phone against a merchant’s terminal or an Alipay Tap! Tag, eliminating the need to open an app, scan a code, or click through multiple screens. Data from early adopters show the solution also allows merchants to integrate customer engagement tools more seamlessly into the one-tap payment experience. FamilyMart, the nation-wide convenience store chain, reports that membership sign-ups at checkout tripled post-integration. Accord
DNIB.com Reports Internet Has 368.4 Million Domain Name Registrations at the End of the First Quarter of 202525.4.2025 00:37:00 EEST | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that, according to the latest Domain Name Industry Brief Quarterly Report from DNIB.com, the first quarter of 2025 closed with 368.4 million domain name registrations across all top-level domains (TLDs), an increase of 4.2 million domain name registrations, or 1.1%, compared to the fourth quarter of 2024. Domain name registrations also increased by 6.1 million, or 1.7%, year over year. The .com and .net TLDs had a combined total of 169.8 million domain name registrations in the domain name base at the end of the first quarter of 2025, an increase of 0.8 million domain name registrations, or 0.5% compared to the fourth quarter of 2024. The .com and .net TLDs had a combined decrease of 2.6 million domain name registrations, or 1.5%, year over year. As of March 31, 2025, the .com domain name base totaled 157.2 million domain name registrations and the .ne
Smart Communications Announces Acquisition of Joisto24.4.2025 16:45:00 EEST | Press release
Smart CommunicationsTM, the leading cloud-based platform for enterprise customer communications, today announces it has acquired Joisto, a cloud data archive company. As a result, customers will now have the ability to seamlessly store, manage and retrieve digital records and documents, while meeting the stringent requirements for data retention that govern regulated industries worldwide. “We’re delighted to incorporate Joisto’s deep expertise in cloud archival into Smart Communications,” said Leigh Segall, CEO of Smart Communications. “Our leading Conversation Cloud Platform already enables our customers to manage sophisticated customer conversations at tremendous scale. With the addition of Joisto, we will extend these capabilities to meet an increasing need for regulatory-compliant and readily accessible storage of these conversations in the cloud. Together we will support customers worldwide as they continue their journey to modernize and transform customer conversations.” Joisto’s
Rimini Street Appoints Joe Locandro as EVP and Chief Information Officer to Lead Global IT Strategy24.4.2025 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the appointment of Joe Locandro as executive vice president (EVP) and chief information officer (CIO). In this role, Locandro will lead Rimini Street’s global IT operations, oversee enterprise systems strategy and drive technology innovation initiatives in support of Rimini Street’s continued growth and client success. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424168093/en/ Rimini Street Appoints Joe Locandro as EVP and Chief Information Officer to Lead Global IT Strategy Deep Technology Leadership Across Range of Industries and Regions Locandro brings more than 25 years of international leadership experience across sectors including energy, aviation, utilities, construction, and entertain
Boomi World 2025: Accelerating What’s Next in AI, Integration, and the Connected Enterprise24.4.2025 16:00:00 EEST | Press release
Boomi™, the intelligent integration and automation leader, is excited to announce that Boomi World 2025 will be held May 12-15, 2025, in Dallas, Texas. This premier event will showcase the latest advancements in AI-driven integration and automation, bringing together industry leaders, innovative thinkers, and Boomi customers and partners to explore how these technologies are reshaping the future. Attendees will gain valuable insights on how to break down silos, streamline operations, and make informed, data-driven decisions through a series of keynote sessions, breakout discussions, and hands-on training opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424969941/en/ Boomi World 2025: Accelerating What’s Next in AI, Integration, and the Connected Enterprise Emceed by technology industry veteran and correspondent Lisa Martin, Boomi World 2025 will feature esteemed speakers, including: Tara Davis-Woodhall and Hu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom